Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunome, Inc. - Common Stock (NQ:IMNM)

20.82 -0.66 (-3.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunome, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Immunome Announces Pricing of Public Offering of Common Stock
From Immunome, Inc.
Via Business Wire
News headline image
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Why Immunome Stock Surged Today ↗
The oncology specialist's targeted therapies could improve thousands of lives. 
Via The Motley Fool
News headline image
Where Immunome Stands With Analysts ↗
 
Via Benzinga
News headline image
Where Immunome Stands With Analysts ↗
 
Via Benzinga
News headline image
Immunome Announces Proposed Public Offering of Common Stock
From Immunome, Inc.
Via Business Wire
News headline image
ENDRA Life Sciences (NASDAQ: NDRA) Advances Health Tech (Alongside KYTX, RADX, GLSI IMNM) With a Next-Generation Treasury Strategy
Via AB Newswire
News headline image
Which stocks are gapping on Monday? ↗
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’ ↗
Via Stocktwits
News headline image
Why Is IMNM Stock Rising Today? ↗
Immunome stock is on track to open at its highest levels in over 20 months, after the company reported positive topline results from its global Phase 3 RINGSIDE trial for a treatment targeting a type... 
Via Stocktwits
News headline image
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Present at Upcoming Investor Conferences
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
This Crocs Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday ↗
 
Via Benzinga
News headline image
This GATX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Infinimmune Announces Research Collaboration with Immunome
From Infinimmune
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Immunome, Inc.
Via Business Wire
News headline image
This Netgear Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday ↗
 
Via Benzinga
News headline image
Immunome (IMNM) Q2 Revenue Surges 382% ↗
Via The Motley Fool
News headline image
Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
These stocks are moving in today's after hours session ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.